Robert J. Hayashi, M.D.  hayashi_r@kids.wustl.edu

Division Chief, Hematology and Oncology
Researcher, Patient Oriented Research Unit
Patient Oriented Research Unit

phone:

Clinical Interests

Dr. Hayashi is a Professor of Pediatrics the Division of Pediatric Hematology/Oncology and an attending physician in Hematology/Oncology and General Pediatrics at St. Louis Children’s Hospital. Dr. Hayashi is board certified in both Pediatrics and Pediatric Hematology/Oncology with clinical interests that include Bone Marrow Transplantation, Non-Hodgkin's Lymphoma and Post-transplant Lymphoproliferative disease (PTLD) and the long term consequences of cancer therapy. He is actively involved in institutional national trials advancing the treatment of patients in these areas.

Education

  • BS, Departmental Honors, Stanford University1982
  • MD, Washington Unversity School of Medicine1986

Training

  • Intern in Pediatrics, St. Louis Chiildren's Hospital1986 - 1987
  • Resident in Pediatrics , St. Louis Children's Hospital1987 - 1989
  • Fellowship in Pediatric Hematology/Oncology, The Johns Hopkins School of Medicine 1989 - 1992

Licensure and Board Certification

  • American Board of Pediatrics 1991
  • Pediatric Hematology/Oncology 1992
  • MO, Missouri Medical Licensure 1994

Honors

  • Departmental Honors, Department of Biology, Stanford University, Stanford California1982
  • Child Health Research Center Award1990 - 1992
  • Physicain Scientist Award1992 - 1997
  • Castle Connolly's America's Top Doctors in Cancer2005 - Pres
  • Castle Connolly's America's Top Doctors2006 - Pres
  • Legacy Award, National Children's Cancer Society2006
  • Developed program for chemotherapy ordering recognized as "Best Practice" by The Joint Commission2009
  • Medical Excellence Award, National Childrens Cancer Society2013

Recent Publications view all (71)


Publication Co-Authors

  1. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review From the Late Effects and Quality of Life Working Committee of the CIBMTR and Complications and Quality of Life Working Party of the EBMT. Biol Blood Marrow Transplant. 2017. PMID:28939455 
  2. Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2017. PMID:28869618 
  3. Increased complications of chronic erythrocytapheresis compared with manual exchange transfusions in children and adolescents with sickle cell disease. Pediatr Blood Cancer. 2017. PMID:28544309 
  4. Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplant. Biol Blood Marrow Transplant. 2017. PMID:28527984 
  5. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less Than Three Years of Age. Biol Blood Marrow Transplant. 2017. PMID:28461213 
  6. Improved survival after acute graft vs host disease diagnosis in the modern era. Haematologica. 2017. PMID:28302712 
  7. Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors. J Pediatr Oncol Nurs. 2017;34(2):106-114. PMID:27251891 
  8. Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study. Lancet Psychiatry. 2016;3(10):965-972. PMCID:PMC5056029  PMID:27639661 
  9. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016;22(9):1734. PMID:27343717 
  10. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016. doi:10.1016/j.bbmt.2016.04.025  PMID:27164064 
  11. Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016;48(1):101. PMID:26711114 
  12. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015. doi:10.1038/ng.3400  PMID:26457647 
  13. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
  14. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.08.023  PMID:26327632 
  15. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015. doi:10.1038/bmt.2015.177  PMID:26237164 
  16. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.05.023  PMID:26033280 
  17. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.05.010  PMID:25981509 
  18. Neurocognitive outcomes and school performance in solid tumor cancer survivors lacking therapy to the central nervous system. J Pers Med. 2015;5(2):83-90. doi:10.3390/jpm5020083  PMID:25867598 
  19. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334 
  20. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015. doi:10.1038/bmt.2015.63  PMID:25822223 
  21. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015. doi:10.1002/pbc.25458  PMID:25755151 
  22. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol. 2015;37(2):e94-e101. doi:10.1097/MPH.0000000000000272  PMID:25333837 
  23. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-74. doi:10.1016/j.bbmt.2014.10.021  PMCID:PMC4326247  PMID:25445023 
  24. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015;21(1):151-8. doi:10.1016/j.bbmt.2014.10.006  PMCID:PMC4272862  PMID:25316109 
  25. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014. doi:10.1016/j.bbmt.2014.07.009  PMID:25042734 
  26. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014;12(1):21-32; quiz 32. PMID:24453290 
  27. Participation and Self -Management Strategies of Young Adult Cancer Survivors Occupational Therapy Journal of Research. 2013;33(1):21-30. 
  28. A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013. doi:10.1093/neuonc/not021  PMID:23460318 
  29. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013;48(3):363-8. doi:10.1038/bmt.2012.166  PMCID:PMC3525761  PMID:22964594 
  30. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer. 2013;60(1):110-5. doi:10.1002/pbc.24198  PMCID:PMC3436954  PMID:22628201 
  31. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am J Transplant. 2012;12(11):3069-75. doi:10.1111/j.1600-6143.2012.04206.x  PMCID:PMC3484187  PMID:22883417 
  32. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2012;10(9):1112-50. PMID:22956810 
  33. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2012;10(9):1112-50. PMID:22956810 
  34. Blueberry Muffin Rash and REspiratory Distress in a Late Preterm INfant Neoreviews. 2012;13:e506. 
  35. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol. 2010;32(2):119-23. doi:10.1097/MPH.0b013e3181cb8593  PMID:20098336 
  36. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223-30. doi:10.1016/j.bbmt.2009.09.021  PMCID:PMC2911354  PMID:19800015 
  37. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;54(2):291-8. doi:10.1002/pbc.22227  PMID:19743300 
  38. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(24):5817-27. doi:10.1002/cncr.24670  PMID:19834960 
  39. The Late-Effects of Childhood Cancer on Occupational Performance and Quality of Life: A Pilot Study Occupational Therapy Journal of Research . 2009;29(3):116-124. 
  40. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant. 2009;43(4):307-14. doi:10.1038/bmt.2008.327  PMCID:PMC2792985  PMID:19011666 
  41. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175-80. doi:10.1038/bmt.2008.133  PMID:18454181 
  42. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(8):4014-21. doi:10.1182/blood-2007-08-106021  PMCID:PMC2288716  PMID:18258798 
  43. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575-8. doi:10.1016/j.jaad.2007.12.037  PMID:18249465 
  44. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008;30(2):130-4. doi:10.1097/MPH.0b013e31815d1d83  PMID:18376265 
  45. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349-53. doi:10.1038/sj.bmt.1705926  PMID:18026148 
  46. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant. 2007;11(3):312-8. doi:10.1111/j.1399-3046.2006.00626.x  PMCID:PMC1930168  PMID:17430489 
  47. Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: A report from the Childhood Cancer Survivors Study. Psychooncology. 2007;16(1):26-37. doi:10.1002/pon.1072  PMID:16921476 
  48. Requirement of high-affinity IL-2-IL-2R interaction for T cell anergy induction. Int Immunol. 2006;18(5):645-51. doi:10.1093/intimm/dxh397  PMID:16574670 
  49. Otolaryngological manifestations of posttransplant lymphoproliferative disorder in pediatric thoracic transplant patients. Int J Pediatr Otorhinolaryngol. 2006;70(2):303-10. doi:10.1016/j.ijporl.2005.07.011  PMID:16125255 
  50. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant. 2005;35(4):361-7. doi:10.1038/sj.bmt.1704743  PMID:15608659 
  51. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-52. doi:10.1038/sj.bmt.1704795  PMID:15592491 
  52. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-6. doi:10.109701.GIM.0000154299.22120.6A  PMID:15714083 
  53. Isolated CNS relapse following stem cell transplantation for juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2003;25(11):910-3. PMID:14608204 
  54. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25(7):539-42. PMID:12847320 
  55. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation. 2003;75(9):1538-43. doi:10.1097/01.TP.0000061607.07985.BD  PMID:12792511 
  56. Childhood cancer survivors' knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002;287(14):1832-9. PMID:11939869 
  57. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463-9. PMID:11481351 
  58. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol. 2001;177(2):449-54. doi:10.2214/ajr.177.2.1770449  PMID:11461881 
  59. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant. 2001;27(10):1059-64. doi:10.1038/sj.bmt.1703032  PMID:11438821 
  60. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23(1):14-8. PMID:11196263 
  61. Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features. Radiology. 2000;217(1):16-25. PMID:11012419 
  62. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1252-5. doi:10.1164/ajrccm.161.4.9901013  PMID:10764320 
  63. Unique CD4(+) T cells in TCR alpha chain-deficient class I MHC-restricted TCR transgenic mice: role in a superantigen-mediated disease process. Int Immunol. 1999;11(9):1581-90. PMID:10464179 
  64. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188(12):2357-68. PMCID:PMC2212434  PMID:9858522 
  65. Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients. AJR Am J Roentgenol. 1998;171(2):375-82. doi:10.2214/ajr.171.2.9694455  PMID:9694455 
  66. Differences between responses of naive and activated T cells to anergy induction. J Immunol. 1998;160(1):33-8. PMID:9551953 
  67. Cytogenetic abnormalities in two cases of neuroblastoma. Cancer Genet Cytogenet. 1994;74(1):30-4. PMID:8194044 
  68. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994;179(4):1215-24. PMCID:PMC2191440  PMID:7908321 
  69. Primitive neuroectodermal tumor arising in the pancreas. Mod Pathol. 1994;7(2):200-4. PMID:7911997 
  70. Identification of Igh-C-linked determinants on suppressor T cell hybrids and factors specific for L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). J Exp Med. 1985;162(3):1044-59. PMCID:PMC2187798  PMID:2411840 
  71. Regulation of biogenic amine methyltransferases by glucocorticoids via S-adenosylmethionine and its metabolizing enzymes, methionine adenosyltransferase and S-adenosylhomocysteine hydrolase. Brain Res. 1985;330(2):209-16. PMID:2985192 
Last updated: 10/10/2017
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130